Q BioMed Inc. | Balance Sheet

Fiscal year is December-November. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
12.60
131.40
1,468.70
824.80
2,684.40
Other Current Assets
-
-
-
2.50
12.50
Total Current Assets
12.60
131.40
1,468.70
827.30
2,696.90
Total Assets
12.60
131.40
1,468.70
827.30
3,196.90
ST Debt & Current Portion LT Debt
-
296.00
2,495.00
-
Accounts Payable
-
-
497.90
471.00
Other Current Liabilities
1.20
91.30
287.40
-
Total Current Liabilities
1.20
387.30
3,280.30
471.00
Long-Term Debt
-
-
231.50
-
Total Liabilities
1.20
387.30
3,511.80
471.00
Common Equity (Total)
11.50
255.90
2,043.10
356.20
Total Shareholders' Equity
11.50
255.90
2,043.10
356.20
Total Equity
11.50
255.90
2,043.10
356.20
Liabilities & Shareholders' Equity
12.60
131.40
1,468.70
827.30

About Q BioMed

View Profile
Address
366 Madison Avenue
New York New York 10017
United States
Employees -
Website http://www.qbiomed.com
Updated 07/08/2019
Q BioMed, Inc. operates as a biomedical acceleration and development company. It is focused on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. The company products include Strontium 89, QBM-001, Uttroside-B, and MAN 01.